126 related articles for article (PubMed ID: 38909218)
1. Effects of time of the day at sampling on CSF and plasma levels of Alzheimer' disease biomarkers.
Orduña Dolado A; Stomrud E; Ashton NJ; Nilsson J; Quijano-Rubio C; Jethwa A; Brum WS; Brinkmalm Westman A; Zetterberg H; Blennow K; Janelidze S; Hansson O
Alzheimers Res Ther; 2024 Jun; 16(1):132. PubMed ID: 38909218
[TBL] [Abstract][Full Text] [Related]
2. Association of Plasma Amyloid, P-Tau, GFAP, and NfL With CSF, Clinical, and Cognitive Features in Patients With Dementia With Lewy Bodies.
Bolsewig K; van Unnik AAJM; Blujdea ER; Gonzalez MC; Ashton NJ; Aarsland D; Zetterberg H; Padovani A; Bonanni L; Mollenhauer B; Schade S; Vandenberghe R; Poesen K; Kramberger MG; Paquet C; Bousiges O; Cretin B; Willemse EAJ; Teunissen CE; Lemstra AW;
Neurology; 2024 Jun; 102(12):e209418. PubMed ID: 38830138
[TBL] [Abstract][Full Text] [Related]
3. Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus.
Lukkarinen H; Tesseur I; Pemberton D; Van Der Ark P; Timmers M; Slemmon R; Janssens L; Streffer J; Van Nueten L; Bottelbergs A; Rauramaa T; Koivisto AM; Herukka SK; Korhonen VE; Junkkari A; Hiltunen M; Engelborghs S; Blennow K; Zetterberg H; Kolb HC; Leinonen V
J Alzheimers Dis; 2021; 80(4):1629-1642. PubMed ID: 33720890
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Plasma Biomarkers for A/T/N Classification of Alzheimer Disease Among Adults of Caribbean Hispanic Ethnicity.
Honig LS; Kang MS; Lee AJ; Reyes-Dumeyer D; Piriz A; Soriano B; Franco Y; Coronado ZD; Recio P; Mejía DR; Medrano M; Lantigua RA; Teich AF; Dage JL; Mayeux R
JAMA Netw Open; 2023 Apr; 6(4):e238214. PubMed ID: 37079306
[TBL] [Abstract][Full Text] [Related]
5. The dynamics of plasma biomarkers across the Alzheimer's continuum.
Guo Y; Shen XN; Wang HF; Chen SD; Zhang YR; Chen SF; Cui M; Cheng W; Dong Q; Ma T; Yu JT
Alzheimers Res Ther; 2023 Feb; 15(1):31. PubMed ID: 36750875
[TBL] [Abstract][Full Text] [Related]
6. Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum.
Benedet AL; Milà-Alomà M; Vrillon A; Ashton NJ; Pascoal TA; Lussier F; Karikari TK; Hourregue C; Cognat E; Dumurgier J; Stevenson J; Rahmouni N; Pallen V; Poltronetti NM; Salvadó G; Shekari M; Operto G; Gispert JD; Minguillon C; Fauria K; Kollmorgen G; Suridjan I; Zimmer ER; Zetterberg H; Molinuevo JL; Paquet C; Rosa-Neto P; Blennow K; Suárez-Calvet M;
JAMA Neurol; 2021 Dec; 78(12):1471-1483. PubMed ID: 34661615
[TBL] [Abstract][Full Text] [Related]
7. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
[TBL] [Abstract][Full Text] [Related]
8. Effects of certain pre-analytical factors on the performance of plasma phospho-tau217.
Bali D; Hansson O; Janelidze S
Alzheimers Res Ther; 2024 Feb; 16(1):31. PubMed ID: 38331843
[TBL] [Abstract][Full Text] [Related]
9. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
10. Effects of acute sleep loss on diurnal plasma dynamics of CNS health biomarkers in young men.
Benedict C; Blennow K; Zetterberg H; Cedernaes J
Neurology; 2020 Mar; 94(11):e1181-e1189. PubMed ID: 31915189
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers - Part 1.
Fonteh AN; Wu X; Astraea N; Elenberger T; Buennagel DP; Sin C; Spezzaferri M; Rising S; Nolty A; Chui HC; Minazad Y; Kloner RA; Arakaki X
Alzheimers Dement; 2023 Dec; 19 Suppl 14():e079861. PubMed ID: 38687559
[TBL] [Abstract][Full Text] [Related]
12. Trajectories of CSF and plasma biomarkers across Alzheimer's disease continuum: disease staging by NF-L, p-tau181, and GFAP.
Wojdała AL; Bellomo G; Gaetani L; Toja A; Chipi E; Shan D; Chiasserini D; Parnetti L
Neurobiol Dis; 2023 Dec; 189():106356. PubMed ID: 37977432
[TBL] [Abstract][Full Text] [Related]
13. Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-Aβ load and cerebrospinal fluid Aβ in a pilot study of Alzheimer's disease.
Lim B; Fowler C; Li QX; Rowe C; Dhiman K; Gupta VB; Masters CL; Doecke JD; Martins RN; Collins S; Diamandis EP
Neurosci Lett; 2020 Jul; 731():135078. PubMed ID: 32450185
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of isolated plasma biomarkers and its combination in neurodegenerative dementias: A multicenter cohort study.
Chen Y; Wang Y; Tao Q; Lu P; Meng F; Zhuang L; Qiao S; Zhang Y; Luo B; Liu Y; Peng G
Clin Chim Acta; 2024 May; 558():118784. PubMed ID: 38588788
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration.
Mattsson-Carlgren N; Grinberg LT; Boxer A; Ossenkoppele R; Jonsson M; Seeley W; Ehrenberg A; Spina S; Janelidze S; Rojas-Martinex J; Rosen H; La Joie R; Lesman-Segev O; Iaccarino L; Kollmorgen G; Ljubenkov P; Eichenlaub U; Gorno-Tempini ML; Miller B; Hansson O; Rabinovici GD
Neurology; 2022 Mar; 98(11):e1137-e1150. PubMed ID: 35173015
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and Prognostic Value of Plasma GFAP in Sporadic Creutzfeldt-Jakob Disease in the Clinical Setting of Rapidly Progressive Dementia.
Bentivenga GM; Baiardi S; Mastrangelo A; Zenesini C; Mammana A; Rossi M; Polischi B; Capellari S; Parchi P
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791145
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
[TBL] [Abstract][Full Text] [Related]
18. Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light.
Schindler SE; Karikari TK; Ashton NJ; Henson RL; Yarasheski KE; West T; Meyer MR; Kirmess KM; Li Y; Saef B; Moulder KL; Bradford D; Fagan AM; Gordon BA; Benzinger TLS; Balls-Berry J; Bateman RJ; Xiong C; Zetterberg H; Blennow K; Morris JC
Neurology; 2022 Jul; 99(3):e245-e257. PubMed ID: 35450967
[TBL] [Abstract][Full Text] [Related]
19. A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer's disease.
Shahpasand-Kroner H; Klafki HW; Bauer C; Schuchhardt J; Hüttenrauch M; Stazi M; Bouter C; Wirths O; Vogelgsang J; Wiltfang J
Alzheimers Res Ther; 2018 Dec; 10(1):121. PubMed ID: 30526652
[TBL] [Abstract][Full Text] [Related]
20. Alzheimer's and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline.
Dark HE; An Y; Duggan MR; Joynes C; Davatzikos C; Erus G; Lewis A; Moghekar AR; Resnick SM; Walker KA
Alzheimers Res Ther; 2024 Apr; 16(1):94. PubMed ID: 38689358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
